Maxcyte Stock Price, News & Analysis

MaxCyte (Nasdaq: MXCT) signed a Strategic Platform License (SPL) with Moonlight Bio on Oct 6, 2025 to support development and scalable manufacturing of Moonlight's engineered T cell therapies for solid tumors. Moonlight gains non-exclusive research, clinical, and commercial rights to MaxCyte's Flow Electroporation® technology and ExPERT™ platform. MaxCyte will receive annual licensing fees and program-related revenue while Moonlight will use GMP-ready electroporation and regulatory support to build clinical manufacturing processes.

MaxCyte (NASDAQ:MXCT), a cell-engineering platform technology company, has announced a significant operational restructuring to optimize costs and accelerate profitability. The plan includes a 34% reduction in global workforce, expected to generate $13.6 million in annual savings.

The company reiterated its 2025 guidance, expecting core revenue to be flat to down 10% compared to 2024, with $5 million in SPL program-related revenue. MaxCyte projects to maintain at least $155 million in cash, cash equivalents, and investments by year-end.

MaxCyte (NASDAQ: MXCT) reported Q2 2025 financial results with mixed performance. The company's core business revenue reached $8.2 million, up 8% year-over-year, while total revenue decreased 18% to $8.5 million due to lower Strategic Platform License (SPL) Program-related revenue. The company added two new SPL clients, bringing the total to 31 agreements.

Key metrics show an installed base of 814 instruments and 42% of core revenue generated by SPL clients. The company updated its 2025 guidance, projecting core revenue to be flat to 10% down compared to 2024, with SPL Program-related revenue expected at approximately $5 million. MaxCyte anticipates ending 2025 with at least $155 million in cash and investments.

MaxCyte (NASDAQ:MXCT) has signed a strategic platform license agreement with Adicet Bio for the use of MaxCyte's Flow Electroporation® technology and ExPERT™ platform. The non-exclusive license grants Adicet Bio research, clinical, and commercial rights to support their gamma delta T cell therapy gene edited programs.

Under the agreement, MaxCyte will receive platform licensing fees and program-related revenue. Adicet Bio will utilize MaxCyte's technology to enhance their proprietary manufacturing process for allogeneic gamma delta T cell therapies, aimed at treating cancer and autoimmune diseases.

The collaboration leverages MaxCyte's ExPERT™ platform, which provides high transfection efficiency, cell viability, and seamless scalability for complex cell engineering applications.

MaxCyte (NASDAQ:MXCT) has signed a Strategic Platform License Agreement with Anocca AB for the use of MaxCyte's Flow Electroporation® technology and ExPERT™ platform. The agreement grants Anocca non-exclusive research, clinical, and commercial rights to support their TCR-T cell therapy development.

Under the agreement, MaxCyte will receive annual licensing fees and program-related revenue. The partnership aims to enhance Anocca's cell therapy manufacturing capabilities, particularly for their lead program targeting KRAS-driven advanced pancreatic cancer currently in clinical development. Anocca recently received GMP compliance certification and manufacturing license from Swedish regulators.

MaxCyte (NASDAQ: MXCT), a cell-engineering platform technology company, has scheduled its second quarter 2025 financial results announcement for August 6, 2025, after the U.S. market close.

The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results. Investors must register online to participate, preferably a day in advance. A live and archived webcast will be available in the "Events" section of MaxCyte's investor relations website.

MaxCyte (MXCT) and Ori Biotech announced a strategic collaboration to enhance cell therapy manufacturing efficiency by integrating their ExPERT™ and IRO® platforms. The partnership aims to optimize yield and streamline manufacturing timelines of MaxCyte-engineered primary T cells. The collaboration will initially focus on CD19 CAR expression via CRISPR knock-in in activated T cells as a test system. MaxCyte's Flow Electroporation® technology, used in over 19 active clinical and commercial programs, will be combined with Ori's automated fluid handling, customizable mixing, and OriConnect® tubeless sterile connection system. This integration is expected to enable faster and more efficient production of clinically relevant quantities of gene-edited T cells.

MaxCyte (NASDAQ: MXCT) reported its Q1 2025 financial results, showing mixed performance. Total revenue decreased 8% to $10.4 million compared to Q1 2024. Core business revenue grew marginally by 1% to $8.2 million, while Strategic Platform License (SPL) Program-related revenue declined 32% to $2.1 million. The company added TG Therapeutics as a new SPL client, bringing total active SPLs to 29. MaxCyte maintained a strong financial position with $174.7 million in cash and investments. The company reiterated its 2025 guidance, expecting core revenue growth of 8-15% and SPL Program-related revenue of approximately $5 million. Gross margin slightly decreased to 86% from 88% in Q1 2024, while net loss increased to $10.3 million compared to $9.5 million in the same period last year.

MaxCyte (NASDAQ: MXCT), a cell-engineering platform technology company, has scheduled its first quarter 2025 financial results announcement for May 7th, 2025, after the U.S. market close. The company will host a conference call with management at 4:30 p.m. Eastern Time to discuss the quarterly performance.

Investors interested in participating in the earnings call must register online, preferably at least one day in advance. A live webcast and recording of the event will be accessible through the 'Events' section on MaxCyte's investor relations website.